PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy

Oncoimmunology
Jan Willem KleinovinkMarieke F Fransen

Abstract

Immunotherapy with PD-1/PD-L1-blocking antibodies is clinically effective for several tumor types, but the mechanism is not fully understood. PD-L1 expression on tumor biopsies is generally regarded as an inclusion criterion for this cancer therapy. Here, we describe the PD-L1-blocking therapeutic responses of preclinical tumors in which PD-L1 expression was removed from cancer cells, but not from immune infiltrate. Lack of PD-L1 expression on malignant cells delayed tumor outgrowth in a CD8+ T cell-mediated fashion, showing the importance of this molecule in immune suppression. PD-L1 expression was evident on myeloid-infiltrating cells in the microenvironment of these tumors and targeting stromal PD-L1 with blocking antibody therapy had additional antitumor effect, demonstrating that PD-L1 on both malignant cells and immune cells is involved in the mechanism of immunotherapeutic antibodies. Importantly, comparable results were obtained with PD-1-blocking therapy. These findings have implications for inclusion of cancer patients in PD-1/PD-L1 blockade immunotherapies.

References

Feb 27, 2001·Nature Immunology·Y LatchmanG J Freeman
Dec 18, 2008·Proceedings of the National Academy of Sciences of the United States of America·Michal MarzecMariusz A Wasik
Dec 18, 2012·Oncoimmunology·Laurence Zitvogel, Guido Kroemer
Nov 28, 2014·Nature·Matthew M GubinRobert D Schreiber
Jan 22, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael A PostowJedd D Wolchok
Apr 19, 2015·Cancer Immunology Research·Tetje C van der SluisThorbald van Hall
Mar 2, 2016·Annual Review of Immunology·Susanne H BaumeisterArlene H Sharpe
Jun 10, 2016·Nature·Keisuke KataokaSeishi Ogawa
Jan 12, 2017·Cancer Immunology Research·Takuro NoguchiRobert D Schreiber

❮ Previous
Next ❯

Citations

Jun 22, 2017·International Journal of Molecular Sciences·Michal Šmahel
Mar 24, 2018·Cellular & Molecular Immunology·Xiaoqing ZhangXuanming Yang
Dec 20, 2017·Frontiers in Immunology·Zijun Y Xu-MonetteKen H Young
Aug 24, 2017·Future Oncology·Fouad AounJoseph Kattan
Sep 28, 2018·International Journal of Cancer. Journal International Du Cancer·Heng Sheng SowJ Sjef Verbeek
Oct 26, 2018·Cancer Immunology, Immunotherapy : CII·Daisuke UmezuKoji Tamada
Jul 20, 2019·Expert Opinion on Biological Therapy·Grégoire MarretChristophe Le Tourneau
Aug 16, 2019·Journal for Immunotherapy of Cancer·Guillaume BeyrendFerry Ossendorp
Aug 28, 2019·Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·Kohei YamashitaHideo Baba
Sep 7, 2019·Science Advances·Johan M S van der SchootFerenc A Scheeren
Jul 1, 2020·Carcinogenesis·Sreekanth Chanickal NarayanapillaiFekadu Kassie
Aug 16, 2017·Oncoimmunology·Jan Willem KleinovinkMarieke F Fransen
May 8, 2018·Frontiers in Oncology·Preeti Kanikarla-MarieDavid G Menter
Dec 7, 2018·JCI Insight·Marieke F FransenFerry Ossendorp
Mar 21, 2019·Cancer Science·Yutaka FujiwaraToshiyuki Kozuki
Aug 24, 2019·Cancers·Carolyn ShembreyFrédéric Hollande
Sep 26, 2020·Cancer Cell International·Seyed Mohammad MiriAmir Ghaemi
Dec 7, 2017·Scientific Reports·Steve Seung-Young LeeStephen J Kron
Jan 18, 2018·The Journal of Clinical Investigation·Haidong TangYang-Xin Fu
Oct 3, 2018·Signal Transduction and Targeted Therapy·David EscorsGrazyna Kochan
Oct 10, 2018·Frontiers in Cellular and Infection Microbiology·Nelita du PlessisGerhard Walzl
Mar 12, 2020·International Journal of Molecular Sciences·Julie VackovaMichal Smahel
May 12, 2018·Genes to Cells : Devoted to Molecular & Cellular Mechanisms·Naoki AoyamaMakoto Mark Taketo
May 15, 2018·Frontiers in Immunology·Brett J HosFerry Ossendorp
Jun 20, 2019·Frontiers in Immunology·Silvia PesceEmanuela Marcenaro
Aug 31, 2017·Cancer Immunology Research·Jan Willem KleinovinkFerry Ossendorp
Feb 14, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Miro ViitalaMaija Hollmén
Apr 26, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mark J A SchoonderwoerdLukas J A C Hawinkels
Jan 21, 2021·Journal for Immunotherapy of Cancer·Xiuting LiuDavid G DeNardo
Nov 14, 2020·Expert Review of Anticancer Therapy·Francesca De FeliceClaudia Marchetti
Jul 2, 2020·Trends in Immunology·Ramon Arens, Ferenc A Scheeren

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsies
flow cytometry

Software Mentioned

Olympus
FlowJo
GraphPad Prism
cellSens
FacsDIVA

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Related Papers

Current Opinion in Obstetrics & Gynecology
Leisha A EmensLaureen S Ojalvo
Cancer Immunology, Immunotherapy : CII
Shamaila Munir AhmadMads Hald Andersen
© 2022 Meta ULC. All rights reserved